Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-13 · accession 0001628280-26-008984 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | 2026-02-13 | VIR | Sabatini Brent | SVP, CAO | S - Sale | $7.79 | -1,530 | 47.9K | -3% | -$11.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-13 | S | D | 1,530 | $7.79 | 47,872 | D | — | — | (F2) Includes 2,290 and 485 shares of common stock acquired by the Reporting Person on May 30, 2025 and November 28, 2025, respectively, pursuant to an employee stock purchase program. |